Early and premature menopause, or premature ovarian insufficiency (POI), affects 1% of women under the age of 40 years. This paper reviews the main aspects of early and premature menopause and their impact on cognitive decline.
advanced Parkinsons and RLS Neupro(rotigotine transdermal system) from UCB/Schwarz is FDA approved as a therapy to treat the signs and...
The FDA Peripheral and Central Nervous System Drugs Advisory Committee decided that the 1,176 patient, randomized, multicentre, double-blind study, known...
Alvogen has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the United States. The product will...
Newron Pharmaceuticals SpA and its partner Zambon SpA announce that a new drug application for safinamide was submitted to the...
Boston Scientific has received FDA approval of its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System for Parkinsons disease.
To determine whether the longitudinal course of PD in patients with the LRRK2 mutation differs from the longitudinal course of PD in patients without the mutation.
An initial review of data at Merck Inc.,from three separate Phase III trials for treatment of Parkinsons disease did not...
Neupro(rotigotine transdermal patch) from UCB/Schwarz is now available again in the US after getting release from the FDA in April...
Newron Pharma has agreed with Zambon SPA to licence safinamide, an add-on therapy to dopamine agonists and levodopa in patients...